Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Fig. 3

Representative tumor characteristics and treatment regimens for NSCLC patients with EGFR mutations. TKI: tyrosine kinase inhibitors; EGFR: epidermal growth factor receptor; PD-L1: programmed death-ligand 1; ICIs: immune checkpoint inhibitors; T1: treatment 1; T2: treatment 2; Ate: atezolizumab; Bev: bevacizumab; Chemo: chemotherapy; (+): positive; (−): negative

Back to article page

Molecular Cancer

ISSN: 1476-4598